EUVIMEDEUVIMED entdecken
Crossref

Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer

Kyoko Yamaguchi iD, Mamoru Ito iD, Taichi Isobe iD, Sakuya Koreishi iD, Ryosuke Taguchi, Koki Uehara, Shohei Ueno, Takashi Imajima iD, Takafumi Kitazono iD, Kenji Tsuchihashi iD, Hirofumi Ohmura iD, Tomoyasu Yoshihiro und 6 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Kyoko Yamaguchi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The impact of genomic alterations on response and resistance to trastuzumab deruxtecan (T-DXd) has not been elucidated. Thus, we sought to identify factors predicting sensitivity to T-DXd in gastric or gastroesophageal junction (G/GEJ) cancer. METHODS We conducted a retrospective study using real-world clinical data and next-generation sequencing–based comprehensive genomic profiling (CGP) data from patients with advanced G/GEJ cancers, collected by the nationwide database in Japan. We analyzed the associations between genomic alterations and the patients' survivals after T-DXd treatment. RESULTS In 114 patients with human epidermal growth factor receptor-2 (HER2)–positive G/GEJ cancer treated with T-DXd, the most frequently altered genes were TP53 (82%), ERBB2 (80%), and CCNE1 (36%). Multivariate Cox regression analysis revealed CCNE1 amplification to be a significant predictor of shorter progression-free survival (PFS) after T-DXd treatment among 91 patients whose CGP samples were obtained before T-DXd (median PFS, 131 days v 189 days; hazard ratio [HR], 1.90 [95% CI, 1.02 to 3.53]; P = .044). Analyses of 1,450 G/GEJ cancers revealed significant CCNE1/ ERBB2 coamplification (41% relative to 11% CCNE1 amplification in ERBB2-nonamplified tumors; P < .0001). ERBB2-activating mutations were also detected in 3.7% of G/GEJ cancers and in 8.8% of HER2-positive G/GEJ cancers treated with T-DXd. Patients with ERBB2-mutated tumors showed shorter PFS than those without ERBB2 mutations after T-DXd treatment (mPFS, 105 v 180 days; P = .046). CONCLUSION CCNE1 amplification may confer primary resistance to T-DXd in HER2-positive G/GEJ cancer, suggesting that the cell cycle could be a potential therapeutic target in CCNE1/ERBB2 coamplified tumors. ERBB2-activating mutation may also attenuate T-DXd efficacy in HER2-positive G/GEJ cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultCamptothecinAntineoplastic Agents, ImmunologicalAged, 80 and over

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCamptothecinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Division of Precision Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Kyoko Yamaguchi, Mamoru Ito, Taichi Isobe, Sakuya Koreishi, Takashi Imajima, Takafumi Kitazono, Kenji Tsuchihashi, Hirofumi Ohmura, Kenro Tanoue, Takahiro Maeda, Eishi Baba

Zitieren

APA

Yamaguchi, K., Ito, M., Isobe, T., Koreishi, S., Taguchi, R., Uehara, K., Ueno, S., Imajima, T., Kitazono, T., Tsuchihashi, K., Ohmura, H., Yoshihiro, T., Tanoue, K., Nishiyori, S., Iwama, E., Maeda, T., Akashi, K., & Baba, E. (2024). Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00681

Vancouver

Yamaguchi K, Ito M, Isobe T, Koreishi S, Taguchi R, Uehara K, et al. Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.23.00681

BibTeX
@article{Yamaguchi2024,
  author = {Yamaguchi, Kyoko and Ito, Mamoru and Isobe, Taichi and Koreishi, Sakuya and Taguchi, Ryosuke and Uehara, Koki and Ueno, Shohei and Imajima, Takashi and Kitazono, Takafumi and Tsuchihashi, Kenji and Ohmura, Hirofumi and Yoshihiro, Tomoyasu and Tanoue, Kenro and Nishiyori, Satoshi and Iwama, Eiji and Maeda, Takahiro and Akashi, Koichi and Baba, Eishi},
  title = {Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00681}
}
Kostenlos starten →